Published in Cancer Immunol Res on February 24, 2015
Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov (2015) 1.23
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
Automated profiling of individual cell-cell interactions from high-throughput time-lapse imaging microscopy in nanowell grids (TIMING). Bioinformatics (2015) 0.83
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers (Basel) (2016) 0.82
Nanotechnologies for biomedical science and translational medicine. Proc Natl Acad Sci U S A (2015) 0.78
Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. J Immunol (2016) 0.75
CAR-T cells are serial killers. Oncoimmunology (2015) 0.75
Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task. Cancer Immunol Res (2015) 0.75
Microchip Screening Platform for Single Cell Assessment of NK Cell Cytotoxicity. Front Immunol (2016) 0.75
Identification and isolation of antigen-specific cytotoxic T lymphocytes with an automated microraft sorting system. Integr Biol (Camb) (2016) 0.75
Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells. PLoS One (2017) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Reversal of the TCR stop signal by CTLA-4. Science (2006) 4.59
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Life and death in peripheral T cells. Nat Rev Immunol (2007) 3.67
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med (1984) 3.06
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood (2011) 2.12
Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther (2004) 2.08
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (2004) 1.99
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood (2014) 1.62
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood (2014) 1.52
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med (2013) 1.48
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One (2013) 1.32
Single-cell analysis of the dynamics and functional outcomes of interactions between human natural killer cells and target cells. Integr Biol (Camb) (2012) 1.30
Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood (2013) 1.15
A novel miniature cell retainer for correlative high-content analysis of individual untethered non-adherent cells. Lab Chip (2006) 1.02
High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One (2014) 0.98
Quantitative high-throughput single-cell cytotoxicity assay for T cells. J Vis Exp (2013) 0.93
Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res (2014) 0.93
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology (2013) 0.88
High throughput single cell bioinformatics. Biotechnol Prog (2009) 0.87
Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin Cancer Res (2015) 1.48
Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant (2014) 1.42
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer (2016) 1.39
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res (2015) 1.13
A benchmark for evaluation of algorithms for identification of cellular correlates of clinical outcomes. Cytometry A (2015) 0.78
Toward deterministic and semiautomated SPADE analysis. Cytometry A (2017) 0.75
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant (2016) 0.75
Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Am J Hematol (2017) 0.75
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant (2016) 0.75
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant (2016) 0.75
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer (2017) 0.75
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning. Cancer (2017) 0.75